Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Sei Investments Co.

Sei Investments Co. lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 47.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 128,016 shares of the company’s stock after buying an additional 41,347 shares during the period. Sei Investments Co.’s holdings in Neurocrine Biosciences were worth $17,624,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Pacer Advisors Inc. increased its stake in Neurocrine Biosciences by 76.1% during the second quarter. Pacer Advisors Inc. now owns 31,890 shares of the company’s stock worth $4,390,000 after acquiring an additional 13,782 shares during the last quarter. Skandinaviska Enskilda Banken AB publ increased its position in shares of Neurocrine Biosciences by 2.5% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 119,837 shares of the company’s stock worth $16,497,000 after purchasing an additional 2,877 shares during the last quarter. Simplify Asset Management Inc. acquired a new stake in shares of Neurocrine Biosciences during the 2nd quarter worth about $3,144,000. Intech Investment Management LLC raised its holdings in Neurocrine Biosciences by 184.0% in the 2nd quarter. Intech Investment Management LLC now owns 68,698 shares of the company’s stock valued at $9,458,000 after buying an additional 44,512 shares during the period. Finally, Seven Eight Capital LP lifted its position in Neurocrine Biosciences by 370.2% in the second quarter. Seven Eight Capital LP now owns 7,862 shares of the company’s stock valued at $1,082,000 after buying an additional 6,190 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Julie Cooke sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $140.19, for a total transaction of $1,401,900.00. Following the sale, the insider now owns 18,202 shares of the company’s stock, valued at $2,551,738.38. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Julie Cooke sold 10,000 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $140.19, for a total value of $1,401,900.00. Following the completion of the sale, the insider now directly owns 18,202 shares of the company’s stock, valued at approximately $2,551,738.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William H. Rastetter sold 14,250 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total value of $2,090,332.50. Following the transaction, the director now owns 37,491 shares in the company, valued at approximately $5,499,554.79. The disclosure for this sale can be found here. Insiders sold 71,798 shares of company stock valued at $10,676,096 over the last three months. 4.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on NBIX. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research note on Monday, September 16th. Citigroup boosted their target price on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. raised their price target on Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, August 29th. Finally, StockNews.com upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Sunday, August 4th. Five research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $162.20.

Neurocrine Biosciences Trading Down 1.7 %

Shares of NBIX stock opened at $114.55 on Thursday. The company has a market cap of $11.53 billion, a P/E ratio of 31.56 and a beta of 0.37. The firm has a fifty day moving average price of $136.67 and a 200 day moving average price of $137.77. Neurocrine Biosciences, Inc. has a 12 month low of $103.63 and a 12 month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.15 by ($0.52). Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. The business had revenue of $590.20 million for the quarter, compared to analyst estimates of $545.98 million. During the same period in the prior year, the company posted $0.95 earnings per share. The company’s revenue was up 30.4% compared to the same quarter last year. On average, equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.